Imlifidase is an endopeptidase known for cleaving anti-Human Leucocyte Antigen donor-specific antibodies (DSA) to allow high-risk kidney transplantation. However, it lacks comprehensive data regarding its effect on alloantibodies targeting other histocompatibility antigens, such as Major Histocompatibility Complex class I chain-related protein A (MICA). This study describes the dynamics of anti-MICA antibodies following imlifidase administration in a kidney transplant recipient with anti-MICA*002 preformed DSA. Imlifidase induced a notable reduction in anti-MICA antibodies, followed by a rebound of the anti-MICA DSA after 14 days. Subsequent to early antibody-mediated rejection, the combination of immunoadsorption and daratumumab infusion proved effective in removing all anti-MICA antibodies at day 45 after transplantation. These findings shed light on the management of anti-MICA antibodies, an area still lacking consensus in current clinical practice. This research underscores the significance of imlifidase in addressing pretransplant anti-MICA and other antibodies directed against non-HLA targets, extending its therapeutic utility in kidney transplantation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.humimm.2024.111213 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evolution of anti-MICA antibodies after imlifidase infusion for a high immunological risk kidney transplantation.
Hum Immunol
January 2025
Service de Néphrologie, Dialyse et Transplantation, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Laboratoire d'ImmunoRhumatologie Moléculaire, Institut national de la santé et de la recherche médicale (INSERM) UMR_S1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France; Laboratoire d'Excellence (LabEx) TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France; Institut Thématique Interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Strasbourg, France. Electronic address:
Imlifidase is an endopeptidase known for cleaving anti-Human Leucocyte Antigen donor-specific antibodies (DSA) to allow high-risk kidney transplantation. However, it lacks comprehensive data regarding its effect on alloantibodies targeting other histocompatibility antigens, such as Major Histocompatibility Complex class I chain-related protein A (MICA). This study describes the dynamics of anti-MICA antibodies following imlifidase administration in a kidney transplant recipient with anti-MICA*002 preformed DSA.
View Article and Find Full Text PDFIsolation of anti-tumor monoclonal antibodies targeting on MICA/B α3 domain by single B cell technology for colon cancer therapy.
Heliyon
August 2024
The People's Hospital of Xishuangbanna Dai Nationality Autonomous Prefecture, Xishuangbanna Dai Nationality Autonomous Prefecture, Yunnan, China.
Colon cancer (CC) is one of the most common gastrointestinal malignancies. Effectiveness of the existing therapies is limited. Immunotherapy is a promising complementary treatment approach for CC.
View Article and Find Full Text PDFNanobody-based CAR NK cells for possible immunotherapy of MICA tumors.
PNAS Nexus
May 2024
Program in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
The glycoproteins MICA and MICB are upregulated on the surface of cells undergoing stress, for instance due to (viral) infection or malignant transformation. MICA/B are the ligands for the activating receptor NKG2D, found on cytotoxic immune cells like NK cells, CD8 T cells, and γδ T cells. Upon engagement of NKG2D, these cells are activated to eradicate the MICA/B-positive targets, assisted by the secretion of cytokines.
View Article and Find Full Text PDFCorrection: The impact of ageing on the distribution of preformed anti-HLA and anti-MICA antibody specificities in recipients from eastern China prior to initial HSCT.
Immun Ageing
April 2024
HLA Lab, Department of Transfusion, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
A novel MICA/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cells.
Biochem Biophys Res Commun
May 2024
Henan Province Engineering Research Center of Innovation for Synthetic Biology, School of Life Sciences and Technology, Xinxiang Medical University, Xinxiang, Henan Province, PR China. Electronic address:
Chimeric antigen receptor (CAR)-modified immune cells have emerged as a promising approach for cancer treatment, but single-target CAR therapy in solid tumors is limited by immune escape caused by tumor antigen heterogeneity and shedding. Natural killer group 2D (NKG2D) is an activating receptor expressed in human NK cells, and its ligands, such as MICA and MICB (MICA/B), are widely expressed in malignant cells and typically absent from healthy tissue. NKG2D plays an important role in anti-tumor immunity, recognizing tumor cells and initiating an anti-tumor response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!